Q-omics provides the consensus-scored CEBPA-DT profile across patient tissues and cancer cell-line models. CEBPA-DT expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CEBPA-DT is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, CEBPA-DT RNA expression shows 18,610 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, THCA, and LSCC as cancer lineages where CEBPA-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CEBPA-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CEBPA-DT survival associations across molecular data types. CEBPA-DT RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CEBPA-DT RNA expression–survival associations across cancer types. High CEBPA-DT expression shows unfavorable associations in UCEC and LIHC, but favorable associations in UVM, READ, KIRP and LUAD. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CEBPA-DT RNA expression.
This table summarizes CEBPA-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CEBPA-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CEBPA-DT shows lower tumor expression in THCA, LUAD, UCEC and BRCA and higher tumor expression in LIHC and KIRP. The THCA box plot shows higher CEBPA-DT RNA expression in normal versus tumor tissue (log2 FC = −2.224, t-test p < 0.001).
This table shows molecular features associated with CEBPA-DT in patient tissues and cancer cell lines. In patient samples, CEBPA-DT shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CEBPA-DT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
